Thinly traded micro cap Eiger BioPharmaceuticals (EIGR +5%) in up on average volume of 62K shares on the heels of its announcement that the FDA agrees with its design for a...
Eiger BioPharmaceuticals (EIGR -0.5%) has completed the enrollment of 18 subjects in its Phase 2 clinical trial, PREVENT, evaluating avexitide (formerly exendin 9-39) in...
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced that it has completed rolling submission of a new drug application (“NDA”) to the FDA for its pipeline...
Intuitive Surgical Inc.’s (NASDAQ:ISRG) fourth-quarter 2017 results, scheduled for release on Jan 25, are expected to show steady growth in instruments and accessories...
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%,...
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.